Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-gp100 TCR-Engineered Lymphocytes + ALVAC Vaccine in Metastatic Melanoma
NCT00610311Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2008
- Primary completion
- Feb 2011
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gp100:154-162 reactive peripheral blood lymphocytes in melanoma, sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR). Started Jan 2008; status: terminated.
02
Drugs
gp100:154-162 reactive peripheral blood lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00610311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610311.